Nuvectra Corporation (NASDAQ:NVTR) released its quarterly earnings results on Tuesday, August 8th. The company reported ($1.07) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.14) by $0.07, Briefing.com reports. Nuvectra Corporation had a negative net margin of 232.31% and a negative return on equity of 56.68%. The business had revenue of $7.20 million for the quarter, compared to the consensus estimate of $5.96 million. During the same period last year, the firm earned ($0.85) earnings per share. The company’s quarterly revenue was up 188.0% on a year-over-year basis.
Shares of Nuvectra Corporation (NASDAQ NVTR) opened at 11.41 on Friday. Nuvectra Corporation has a 52 week low of $4.63 and a 52 week high of $15.00. The stock’s market capitalization is $122.08 million. The stock has a 50 day moving average of $12.17 and a 200-day moving average of $9.40.
Several research firms have weighed in on NVTR. B. Riley reiterated a “buy” rating and issued a $12.00 price target on shares of Nuvectra Corporation in a research report on Wednesday, May 10th. Zacks Investment Research upgraded shares of Nuvectra Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. Piper Jaffray Companies reiterated a “neutral” rating and issued a $14.00 price target on shares of Nuvectra Corporation in a research report on Thursday, July 6th. TheStreet raised shares of Nuvectra Corporation from a “d” rating to a “c-” rating in a research note on Monday, June 19th. Finally, ValuEngine raised shares of Nuvectra Corporation from a “sell” rating to a “hold” rating in a research note on Friday, June 16th. Three analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Nuvectra Corporation presently has an average rating of “Hold” and an average price target of $10.50.
Nuvectra Corporation Company Profile
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company’s Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company’s commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs.
What are top analysts saying about Nuvectra Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Nuvectra Corporation and related companies.